Omalizumab in chronic spontaneous urticaria

Abstract

<p class="abstract"><strong>Background:</strong> Chronic spontaneous urticaria is a common skin disorder affecting 0.5 to 1% of people in the general population. There are a variety of treatment options available without much successful outcome. Omalizumab is a novel treatment option which can be used in the treatment of chronic spontaneous urticaria. The aim of our study is to assess the efficacy of omalizumab in chronic spontaneous urticaria.</p><p class="abstract"><strong>Methods:</strong> A retrospective analysis of data of 10 patients with chronic spontaneous urticaria who were treated with three doses of omalizumab in our institution. Doses were given at monthly intervals for 3 months and they were followed for another 6 months. Response was assessed using urticaria activity score.<strong></strong></p><p class="abstract"><strong>Results:</strong> 70% of patients had well controlled urticaria with 3 doses of omalizumab by the end of 9 months.</p><strong>Conclusions:</strong>Omalizumab is a safe and effective treatment option in the management of chronic spontaneous urticaria. <p> </p>